CRISPR/Cas9 Patent Battle: What's Happened, What's Next?
With the gene editing pipeline at stake, academic research institutions are battling for ownership of the foundational patents in CRISPR/Cas9 technology. A new report from Datamonitor Healthcare spells out the IP challenges and provides a timeline of key patent decisions.
You may also be interested in...
Despite being ineligible to license its CRISPR technology for human gene and cell therapy applications, ERS is doing considerable business with biopharmas for internal R&D projects.
The US patent office's initial ruling on CRISPR patents that granted the Broad Institute a victory at the expense of the University of California caps the first major skirmish in what will be a long, drawn-out corporate legal battle.
CRISPR technology was invented less than four years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, transforming the way gene editing is done and offering its potential use in a wide array of therapies. Here Scrip tells you all you need to know about this disruptive technology.